KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vertex Pharmaceuticals (VRTX) Long-Term Debt Repayments (2016 - 2018)

Vertex Pharmaceuticals has reported Long-Term Debt Repayments over the past 8 years, most recently at $8.1 million for Q4 2018.

  • Quarterly results put Long-Term Debt Repayments at $8.1 million for Q4 2018, up 76.56% from a year ago — trailing twelve months through Dec 2018 was $27.9 million (up 48.58% YoY), and the annual figure for FY2018 was $27.9 million, up 48.58%.
  • Long-Term Debt Repayments for Q4 2018 was $8.1 million at Vertex Pharmaceuticals, up from $5.7 million in the prior quarter.
  • Over the last five years, Long-Term Debt Repayments for VRTX hit a ceiling of $19.7 million in Q4 2015 and a floor of -$24.0 million in Q4 2014.
  • Median Long-Term Debt Repayments over the past 5 years was $4.8 million (2017), compared with a mean of $5.3 million.
  • Biggest five-year swings in Long-Term Debt Repayments: plummeted 1748.01% in 2014 and later skyrocketed 13426.8% in 2016.
  • Vertex Pharmaceuticals' Long-Term Debt Repayments stood at -$24.0 million in 2014, then skyrocketed by 181.99% to $19.7 million in 2015, then plummeted by 78.31% to $4.3 million in 2016, then grew by 7.97% to $4.6 million in 2017, then skyrocketed by 76.56% to $8.1 million in 2018.
  • The last three reported values for Long-Term Debt Repayments were $8.1 million (Q4 2018), $5.7 million (Q3 2018), and $4.9 million (Q2 2018) per Business Quant data.